Research article
Bromocriptine protects against delayed neuronal death of hippocampal neurons following cerebral ischemia in the gerbil

https://doi.org/10.1016/0022-510X(94)00239-KGet rights and content

Abstract

Bromocriptine, a dopamine D2 receptor agonist, has widely been used for patients with Parkinson's disease. In this study, we examined its neuroprotective effects against neuronal damage in the CA1 subfield of the hippocampus following experimental cerebral ischemia in the Mongolian gerbil. Forebrain ischemia was induced by occlusion of bilateral common carotid arteries for 3 min. Bromocriptine, at a dose of 0.3 or 3 mg/kg, was injected i.p. 30 min before the onset of ischemia. Histopathological observations showed that neuronal damage to hippocampal CA1 neurons, which was seen 7 days after ischemia in vehicle-treated animals, was prevented by bromocriptine treatment. Immunohistochemical staining for copper/zinc superoxide dismutase and manganese superoxide dismutase decreased markedly in the CA1 neurons of vehicle-treated animals 2 days after ischemia when histological neuronal destruction was not yet seen, but was well preserved in bromocriptine-treated animals. The present findings show that bromocriptine protects against ischemia-induced neuronal damage, and that the mechanism of the neuroprotection may relate to the preservation of SODs. Bromocriptine, which was recently shown to be a potent free radical scavenger, may have a potent neuroprotective action against disorders including ischemic stroke.

References (31)

  • H.B. Demopoulos

    The basis of the free radical pathology

  • I. Fridovich

    The biology of oxygen radicals. The superoxide radicals is an agent of oxygen toxicity: superoxide dismutase provide an important defense

    Science

    (1978)
  • S. Imaizumi et al.

    Liposome-entrapped superoxide dismutase reduces cerebral infarction in cerebral ischemia in rats

    Stroke

    (1990)
  • H. Kinouchi et al.

    Attenuation of focal cerebral ischemic injury in transgenic mice overexpressing CuZn superoxide dismutase

  • N. Kurobe et al.

    Sensitive immunoassay of rat CuZn superoxide dismutase: concentrations in the brain, liver, and kidney are not affected by aging

    Biomed. Res.

    (1990)
  • Cited by (52)

    • Neuroprotective effects of dopamine D2 receptor agonist on neuroinflammatory injury in olfactory bulb neurons in vitro and in vivo in a mouse model of allergic rhinitis

      2021, NeuroToxicology
      Citation Excerpt :

      Evidence shows that dopamine D2 receptor modulates glutamate-induced neurotoxicity (Garside et al., 1996; Sawada et al., 1998). Dopamine D2 receptor agonists have shown a protective effect on the hippocampus and substantia nigra striatum after ischemia (Hall et al., 1996; Liu et al., 1995). Systemic administration of the glutamatergic agonist alginic acid resulted in the death of hippocampal cells in dopamine D2 receptor knockout mice but not wild-type mice (Bozzi and Borrelli, 2002; Bozzi et al., 2000).

    • A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome

      2021, Cell Reports
      Citation Excerpt :

      Of the compounds identified in this study, bromocriptine showed the most compelling activity across the panel of assays, including protective effects in models of skeletal muscle calcium dysregulation, Wolfram syndrome, oxygen-glucose deprivation, T2D, and stroke. Bromocriptine was previously reported to protect hippocampal neurons from ischemic insult in gerbils (Liu et al., 1995) and was similarly reported to improve ischemia and reperfusion injury in heart (Gao et al., 2013) and kidney (Narkar et al., 2004). Ergot alkaloids, such as bromocriptine, have been postulated to cause myocardial infarction and stroke when used clinically (Larrazet et al., 1993); however, this view is controversial, as subsequent studies have found no association with ischemic injury (Arbouw et al., 2012).

    • Simultaneously changes in striatum dopaminergic and glutamatergic parameters following hypoxic-ischemic neuronal injury in newborn piglets

      2012, European Journal of Paediatric Neurology
      Citation Excerpt :

      Considerable evidence with microdialysis confirms that a large increase in extracellular dopamine occurs in H-I BGI,3 and interruption of the nigrostriatal pathway may relieve ischemic neuronal injury in striatum.27,28 Several studies suggested that either a dopamine D1R or D2R antagonist provided neuroprotection from H-I injury,3,32,33 whereas other studies demonstrated dopamine D2R agonists had a protective effect against both hippocampal and nigrostriatal damage after ischemia.34–36 Numerous reports have documented that excessive glutamate, through NMDA/AMPA receptors, activates the excitotoxic process.29–31

    • Bromocriptine methylate suppresses glial inflammation and moderates disease progression in a mouse model of amyotrophic lateral sclerosis

      2011, Experimental Neurology
      Citation Excerpt :

      It has also been shown that BRC confers protection against oxidative stress-induced cell death (Lim et al., 2008). Further, BRC exerts protective activity against ischemic neuronal insults in gerbils (Liu et al., 1995; O'Neill et al., 1998). These findings suggest that BRC could be a therapeutic agent for ALS besides Parkinson's disease.

    • Neuroprotection in parkinson's disease

      2005, Principles of Treatment in Parkinson's Disease
    View all citing articles on Scopus
    View full text